BeOne Medicines at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

BeOne Medicines takes part in 1 session at ESMO 2026 in Madrid, and exhibits at Booth 8026. Its program centres on non-small cell lung cancer across the course of the disease. It covers immunotherapy in early-stage disease through to new kinds of treatment for advanced disease.

OrganizationESMO 2026 Attendance
beonemedicines.com
Large pharmaExhibitor
Global oncology company, formerly BeiGene, marketing zanubrutinib and tislelizumab.
Booth
Exhibiting at Booth 8026
Satellite
Sun Oct 25
13:00–14:30
BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:​From Early-Stage Immunotherapy to New Modalities in Advanced Disease
Sponsored session · with University of Turin, Hospital Universitario Puerta de Hierro Majadahonda
Lung & thoracic cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from BeOne Medicines

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction